CRUK Cambridge Centre

  • Earliest genetic roots of childhood kidney cancer discovered
  • Blocking survival mechanism to tackle melanoma treatment resistance
  • Olympic athletics official with throat cancer backs Right Now campaign
  • Cambridge researchers win 3 Excellence Awards at NCRI conference
  • Cambridge to lead next generation radiotherapy research
  • Cambridge scientists receive funding boost to detect cancer earlier
  • Our Structure and Strategy - Beyond 2019
  • Clinical trial found my cancer and saved my life

The CRUK Cambridge Centre is a dynamic collaboration of researchers, clinicians, and the pharmaceutical and biotech industries based in the Cambridge area. We combine world-class science and technology with excellent patient care to pioneer new ways to prevent, detect and treat cancer.

By working together across different disciplines, we are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.

Patient care and clinical research
We offer a leading cancer care specialist service at Addenbrooke’s Hospital. We are committed to translating our clinical research to improve patient outcomes by recruiting the highest proportion of patients onto clinical trials in the UK.
Over 140 research groups work together across traditional academic, commercial and clinical boundaries. We connect cutting-edge science and technology from different disciplines to shed new light on preventing and controlling cancer.
Education and training
We educate and train the next generation of cancer scientists and clinicians. Working with the University of Cambridge we provide a stimulating learning environment for undergraduates, graduates, and postdoctoral researchers.

Subscribe to Centre News Latest news and events from CRUK Cambridge Centre

Cambridge scientists have received two out of seven new prostate cancer awards from the charity Prostate Cancer Research Centre (PCRC).
New research indicates metal-organic frameworks (MOFs) could present a viable platform for delivering a potent anti-cancer agent, known as siRNA, to cells.
Simple new blood tests will help doctors decide on the best treatment for patients with germ cell tumours.